Oncology Pipeline
Sibylla is building a pipeline leveraging the power of protein degradation by folding interference
Sibylla’s platform allows the identification of folding interfering degraders acting against difficult-to-drug targets. Due to the unique mechanism of action, we differentiate our small molecules from drugs currently on the market or in development. Our pipeline comprises different internal oncological targets in the discovery and optimization phase.
Pipeline led by Cyclin D1 degrader for initial development in HR+ breast cancer
Our oncology pipeline is led by a Cyclin D1 degrader. Cyclin D1 (CCND1) is a validated driver of cancer cell proliferation, and its overexpression promotes transformation to malignant phenotypes while driving resistance to chemotherapy and CDK4/6 inhibitors. The target is amplified in 15% and over-expressed in 30–50% of human breast cancers, as well as in lung, sarcoma, and colon cancers. Despite its prevalence, Cyclin D1 has remained historically undruggable.
By developing a folding interference small molecule with a degradation outcome, Sibylla aims to exploit this well-established oncogenic pathway. This approach has the potential to unlock next-generation therapies for cancers resistant to current standard-of-care treatments, as well as novel options for indications with high unmet need. We are advancing this asset toward an IND for initial clinical development in HR+ breast cancer, with potential for broader positioning across other CCND1-driven tumor types.